EUVIMEDEUVIMED entdecken
Open Access

Immunotherapy with anti‐G D2 monoclonal antibody in infants with high‐risk neuroblastoma

Brian H Kushner iD, Shakeel Modak, Kim Kramer, Ellen M Basu, Fiorella Iglesias-Cardenas, Stephen S Roberts, Nai-Kong V Cheung

International Journal of Cancer · 15.01.2023 · 152 (2) · 259-266

DOI: 10.1002/ijc.34233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 17.08.2022. Verfasst von Brian H Kushner und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Posterior Leukoencephalopathy Syndrome, Neuroblastoma, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Anti‐G D2 monoclonal antibodies (mAb) improve the prognosis of high‐risk neuroblastoma (HR‐NB). Worldwide experience almost exclusively involves toddlers and older patients treated after multimodality or second‐line therapies, that is, many months postdiagnosis. In contrast, at our center, infants received anti‐G D2 mAbs because this immunotherapy started during or immediately after induction chemotherapy. We now report on the feasibility, safety, and long‐term survival in this vulnerable age group. Thirty‐three HR‐NB patients were 2.5× higher (~270 mg/m 2 /cycle) than 3F8, dinutuximab, and dinutuximab beta (70‐100 mg/m 2 /cycle). HR‐NB in infants proved to be highly curable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Posterior Leukoencephalopathy SyndromeNeuroblastomaAntineoplastic AgentsHumansInfantMiceAnimalsAgedNeoplasm Recurrence, LocalAntibodies, MonoclonalImmunotherapyImmunologic FactorsGlycolipidsAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

3F8immunotherapyinfantsnaxitamabneuroblastoma

Substanzen

Antibodies, MonoclonalImmunologic FactorsAntineoplastic AgentsnaxitamabGlycolipidsAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Brian H Kushner

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Kushner, B. H., Modak, S., Kramer, K., Basu, E. M., Iglesias-Cardenas, F., Roberts, S. S., & Cheung, N. V. (2023). Immunotherapy with anti‐G D2 monoclonal antibody in infants with high‐risk neuroblastoma. International Journal of Cancer, 152(2), 259-266. https://doi.org/10.1002/ijc.34233

Vancouver

Kushner BH, Modak S, Kramer K, Basu EM, Iglesias-Cardenas F, Roberts SS, et al. Immunotherapy with anti‐G D2 monoclonal antibody in infants with high‐risk neuroblastoma. International Journal of Cancer. 2023;152(2):259-266. doi:10.1002/ijc.34233

BibTeX
@article{Kushner2023,
  author = {Kushner, Brian H and Modak, Shakeel and Kramer, Kim and Basu, Ellen M and Iglesias-Cardenas, Fiorella and Roberts, Stephen S and Cheung, Nai-Kong V},
  title = {Immunotherapy with anti‐G D2 monoclonal antibody in infants with high‐risk neuroblastoma},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {152},
  number = {2},
  pages = {259--266},
  doi = {10.1002/ijc.34233}
}
Kostenlos starten →